Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

What's Next in Pfizer's M&A Ramp-Up?

TheMotleyFool

0 0

Despite record-breaking earnings, a rock-bottom valuation, and a top-notch dividend yield, Pfizer's (NYSE: PFE) shares have slid by an unsightly 17.3% so far this year.

Pfizer's stock price has been under pressure this year for a variety of reasons, including but not limited to the following:

Over the past two years, the drugmaker has significantly ramped up its deal-making in an effort to add $25 billion of risk-adjusted revenue by 2030. Here are Pfizer's most significant deals over this period:

Source Fool.com

Like: 0

PFE

Teilen